Johnson & Johnson Update: Wave 4 Correction Nearing CompletionAs discussed on November 14, 2025, Johnson & Johnson was still tracking an extended wave 3 structure with further upside potential. Since then, price has turned lower and retraced more deeply than initially expected, but the move still appears corrective rather than a trend reversal.
The current decline continues to respect key trendline support from the June 2025 lows, suggesting the pullback is likely part of a higher-degree wave 4 correction, potentially unfolding as a complex WXY structure. From a broader perspective, the larger bullish impulse from early 2025 still appears incomplete, leaving room for a possible final wave 5 to the upside once the correction completes. Key support is now seen at 215–225, with deeper support at 210–200 (38.2% retracement).
Highlights
. Pullback still looks counter-trend, complex WXY correction
. Key support zone at 215–225
. Next support near 210-200 (38.2%)
. Bullish wave five still possible on higher timeframe 
Long
$JNJ The Safest Stock on the Planet. Pulling Back. Monthly BUY!If you had to pick one stock to buy and forget for a decade, most serious investors would at least consider Johnson and Johnson. 🧠
64 consecutive years of dividend increases. AAA credit rating. Two of the strongest franchises in global healthcare. A pipeline stuffed with blockbuster drugs. 💊
The stock has pulled back hard from the 52 week high and the monthly chart has printed a clean demand zone. Price has not yet reached it. That is the setup. ⏳
Q1 2026 results were strong across the board. 🏆 Revenue hit $24.1 billion, up 9.9% year over year, beating the $23.6 billion consensus by $500 million. 💰 Adjusted EPS came in at $2.70, beating expectations of $2.68. 🎯 Innovative Medicine sales hit $15.4 billion, up 11.2%, powered by Darzalex up 22.5% operationally and Tremfya up 68.3% operationally. 🚀
MedTech sales hit $8.6 billion, up 7.7%, led by strength in electrophysiology, cardiovascular and orthopaedics. 💪 The company now has 28 platforms or products generating at least $1 billion in annual revenue.
That is not a pipeline. That is a machine. ⚡
Management raised guidance across every metric. 📈 Full year 2026 reported sales guidance was lifted to a midpoint of $100.8 billion, implying 7% growth. 💵 Adjusted EPS guidance was raised to a midpoint of $11.55, also implying 7.1% growth. Pre-tax operating margin is expected to improve by at least 50 basis points in 2026. 🎯
The board raised the quarterly dividend 3.1% from $1.30 to $1.34 per share, lifting the annual rate to $5.36 and extending one of the most remarkable dividend streaks in market history to 64 consecutive years. 🏅
The pipeline is equally compelling. 🔬 ICOTYDE was approved as the first and only targeted oral peptide for plaque psoriasis. TECVAYLI plus Darzalex Faspro was approved for relapsed or refractory multiple myeloma. VARIPULSE Pro received European approval with a new pulse sequence that is five times faster. 🤯 JNJ presented multiple milestone clinical trial readouts at ASCO 2026 across autoimmunity, oncology and myeloma. Management has guided towards double digit EPS growth by the end of the decade. 📅
The 52 week range sits between $149.04 and $251.71. 📊 17 analysts cover the stock with 12 Buy ratings and zero Sell ratings. Average analyst price target is $266.40 with a high target of $285.00. Dividend yield sits at 2.30%. Next earnings are due 15 July 2026. 🐂
Now the key point. ⚠️ Price has NOT yet reached the entry zone. ⏳ The monthly demand zone sits at $185.55, well below where price is currently trading at $232. This is a trade that requires patience. Set the alert. Wait for price to come to the level. Do not chase it. 🧘
🟢 Buy Zone ~ $185.55 area (0.382 Fibonacci Monthly)
⚠️ Price has not yet reached this zone. Wait for price to pull back to the level before entering.
💰 Entry: $185.55
🛑 Stop: $174.99 (5.691% below entry)
🎯 Target: $280.97 (51.4% upside from entry)
📈 Risk/Reward Ratio: 9.04
💵 Annual Dividend: $5.36 per share (2.30% yield)
🏅 Consecutive Dividend Increases: 64 years
🌍 52 Week Range: $149.04 to $251.71
📅 Next Earnings: 15 July 2026
64 years of dividend raises. 🏅 $100 billion revenue year. 💊 12 analysts say Buy. 🐂 Set the alert at $185.55 and let price come to you. 🚀
⚠️ Not financial advice. Manage your risk. Long 
Long 
Could we see another push higher for JNJWhile many believe there is a convincing top on JNJ at the 251 zone, which would indicate a much more meaningful correction below the 200 zone, evidence suggests that the 251 zone is more likely to be a lower degree, and that support in the 208 - 215 zone should hold. That said, from that support, Elliott Wave guidelines would suggest we look for another five-wave structure to the upside, in what would be a larger degree extended wave five. I base this on the following evidence:
-Elliott wave guidelines suggest there should be bearish divergence between wave 3 and 5, and we should look for that divergence on a fractile basis to support the count. Keep in mind that the higher the timeframe of divergence, the more confirmation provided. That said, there is a lack of bearish weekly divergence between the December 15th 2025, weekly high at 215, and the March 2nd 2026, weekly high at 251, which would suggest that the 251 high is more likely not a wave 5 top, and instead a wave 3 top. Therefore, we would be looking for a pullback and one more high to the upside to create that weekly divergence.
- While volume is one of the most simple indicators, it is often overlooked, which is a huge mistake. Volume is provided in real time and is not based on lagging information, like so many other indicators. It must be noted that approximately 90% of market volume is created by informed institutional activity. That said, when we look at the weekly volume coming down from the 251 high, it does not indicate a more meaningful correction. In fact, it is declining in a manner that would suggest declining interest in lower prices, which is a clue that the nearest support is more likely to hold. The nearest weekly support is in the 209 area. Therefore, I would look for the market to pivot in that zone of support.
- Lastly, Elliott Wave guidelines also suggest that wave four pullbacks typically target the previous lower degree's wave four target zone, which the target of 209 is in. This further supports the case for a pullback to 209, where JNJ may pivot and head toward a new all-time high.
If JNJ holds support and we see a push for one more all-time high to complete the higher degree impulse structure, where should we look to forecast the new all-time high? To answer that, we must look at the larger degree structure, and the lower next degree wave five structure we are likely currently in, which would suggest the 300% extension around 272 as a likely forecasted target for the top. Long 
Long 
JOHNSON & JOHNSON Huge -20% correction for 2026.Johnson & Johnson (JNJ) has been trading within a Channel Up since the 2008/09 U.S. Housing Crisis. This pattern has so far had four major correction events, technically its Bearish Legs, which on macro terms they are Bear Cycles.
Its recent March 2026 High almost touched the top of this 18-year pattern and since the 1M RSI also hit the top of its multi-year Resistance Zone, it is technically very likely that the market is starting its new (5th) Bear Cycle.
All previous ones broke below the 1W MA50 (blue trend-line), bottoming on at least the 0.382 Fibonacci retracement level from the last Low. On average, the total drop has been at least -20%.
As a result, if the market has topped indeed, we expect this 2026 correction to target at least $205, which is slightly above the 0.382 Fib and -20% projected decline. At the same time, it would test the 0.5 Channel Fib, a trend-line that all previous corrections had hit.
---
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
---
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇 Short 
JNJ » Bullish Market Structure + Risk-Defined Swing💊 JOHNSON & JOHNSON (NYSE:JNJ) 🚀
📊 Professional Bullish Swing Trade Analysis | "Thief Strategy" Edition
Status: 🟢 BULLISH | Timeframe: Swing Trade (3-7 Days) | Risk Level: Moderate
🎯 CURRENT MARKET SNAPSHOT 📈
Current Price: $205.42 USD | 52-Week Range: $140.68 - $215.19 | Market Cap: $505.28B
Volume: 3.7M+ | Dividend Yield: 2.55% | PE Ratio (TTM): 19.83
💡 BULLISH THESIS 🔥
Johnson & Johnson is positioned for renewed momentum heading into 2026, backed by multiple catalysts. The healthcare giant reported Q3 2025 revenue of $23.99B (beating estimates of $23.76B) with EPS of $2.80 exceeding the $2.76 forecast. The company declared a $1.30 Q1 2026 dividend and has recently showcased impressive pipeline strength:
✅ FDA Priority Voucher secured for pipeline acceleration
✅ $3.05B Halda Therapeutics acquisition completed — adding prostate cancer therapy HLD-0915
✅ OTTAVA Robotic Surgical System submitted for FDA De Novo classification
✅ Positive Phase 2b JASMINE data for nipocalimab in SLE (systemic lupus erythematosus)
✅ Orthopedics spinoff planned — DePuy Synthes separation within 18-24 months
✅ $55B U.S. investment deal with Trump administration for drug cost accessibility
✅ 2026 revenue guidance: >5% growth expected (exceeding consensus)
📍 TECHNICAL SETUP: "THIEF STRATEGY" (MULTI-LAYER ENTRY) 🎯
The "Thief Strategy" uses layered limit orders to accumulate at multiple support levels, maximizing entry efficiency and risk management. This professional approach reduces slippage and emotional trading.
ENTRY LEVELS (Descending Order - Scale In):
🎯 Layer 1 (Most Aggressive): $208.00 — Initial support near recent pullbacks (33% position)
🎯 Layer 2 (Core Position): $210.00 — Strong consolidation zone (33% position)
🎯 Layer 3 (Last Buy): $215.00 — Previous 52-week high vicinity, 4.75% dip zone (34% position)
PRO TIP: If price rallies immediately, enter on dips to these levels rather than forcing entries.
🎪 RESISTANCE LEVEL - "POLICE BARRICADE" 🚨
TARGET PROFIT ZONE: 📍 $223.00 ⭐
Rationale:
Technical Resistance: Historical resistance cluster + 8.8% upside from $205.42
Fundamental Support: Analyst average price target = $209.27 (with some bullish targets at $230)
RBC Capital Markets raised target to $230 from $209 — Outperform rating active
Overbought Zone: RSI caution indicated above $223 suggests profit-taking likely
Earnings Trigger: January 21, 2026 earnings catalyst could drive volatility near target
⚠️ CRITICAL NOTE: This target represents a professional resistance + overbought zone. It is YOUR responsibility to determine exit timing based on your risk tolerance, technical confirmation, and market conditions. Not all targets will be achieved in every trade.
🛑 STOP LOSS PROTECTION 🔴
HARD STOP: $204.00 (Critical Floor)
Rationale:
-0.6% risk from current price — tight but effective
Recent support level — psychological floor below current consolidation
Protects against gap-down risk on negative news (talc litigation overhang, FDA delays)
Risk/Reward Ratio: 1:15+ if target achieved ($223 - $204 = $19 profit vs $1.42 risk)
⚠️ DISCLAIMER: We do NOT recommend using ONLY this SL. This is a baseline suggestion for swing traders. Adjust based on your portfolio heat, account size, and risk appetite. Consider partial takes at $213, $218, and $223 instead of holding all the way.
📰 FUNDAMENTAL & ECONOMIC CATALYSTS 🌍
IMMEDIATE CATALYSTS (Next 30 Days):
📅 January 21, 2026 — Q4 2025 Earnings Report (Before Market Open)
Consensus EPS Forecast: $2.53
Watch for: FY2026 guidance >5% growth reaffirmation, pipeline updates
🏥 Ongoing FDA Review Pipeline:
OTTAVA robotic system (De Novo pathway = 12-24 month timeline)
Multiple neuroscience drug submissions (CAPLYTA, SPRAVATO data presentations ongoing)
💰 Dividend Strength:
Dividend Aristocrat: 62+ consecutive years of dividend increases
Q1 2026 Dividend: $1.30/share (ex-dividend Feb 24, 2026)
Safe income stream supports stock stability
MACRO FACTORS FAVORING HEALTHCARE:
CMS 5.06% Medicare Advantage rate increase for 2026 — Benefits managed care ecosystem
Low sector valuations — Healthcare ETFs trading at discounts despite 19% 6-month gains
FDA on track for record approvals — Supporting pharma/medtech growth narrative
GLP-1 weight-loss drug market — Expected to grow 18.54% CAGR through 2030 ($13.84B→$48.84B)
Aging population dynamics — Structural tailwind for healthcare spending
RISKS TO MONITOR:
⚠️ Talc litigation overhang — Jan 2026 $40M verdict (appeal ongoing); could impact sentiment
⚠️ Patent expirations — STELARA losing exclusivity
⚠️ Tariff impacts — 39% of healthcare execs cite 2026 tariff strategy concerns
⚠️ Pipeline uncertainty — FDA approvals not guaranteed; clinical trial failures possible
💰 RELATED PAIRS TO WATCH 🔗
NYSE:ABBV (AbbVie) — High correlation 📈 | Dividend King powerhouse | Watch for Skyrizi/Rinvoq momentum
NYSE:LLY (Eli Lilly) — High correlation 📈 | GLP-1 obesity drug leader | 12%+ YoY growth driving sector
NYSE:UNH (UnitedHealth) — Moderate correlation 📈 | Managed care strength | Benefiting from 5.06% MA rate increase
NYSE:PFE (Pfizer) — Moderate correlation 📈 | GLP-1 strategy pivot | Seagen cancer platform driving growth
AMEX:XLV (Healthcare ETF) — Very High correlation 📈 | Sector momentum indicator | Best for diversified exposure
🎯 PRO TIP: If LLY/ABBV/UNH are rallying, JNJ typically follows within 1-3 sessions due to sector rotation!
📊 SWING TRADE EXECUTION CHECKLIST ✅
Pre-Entry: Confirm no major news events same day
Entry Phase: Place limit orders at $208/$210/$215 (allow 24-48 hours to fill)
Position Management: Scale in gradually; don't FOMO all-in at once
Stop Loss: Hard stop at $204.00 (non-negotiable)
Profit Targets: Consider partial exits: 33% at $213 | 33% at $218 | 34% at $223
Time Stop: Exit if still underwater after 7 trading days (time decay for swing trades)
Earnings Guard: Close or reduce position 24 hours before Jan 21 earnings to avoid gap risk
💎 KEY TAKEAWAY 🎯
JNJ presents a textbook bullish swing setup with multiple tailwinds (earnings catalyst, pipeline momentum, healthcare sector rotation, strong dividend). The "Thief Strategy" layered entry approach provides mechanical discipline and risk control for swing traders. Target $223 is realistic based on analyst consensus, but profit-taking is likely near resistance — manage your own exit accordingly.
Healthcare sector momentum is building into 2026. JNJ's defensive moat + growth catalysts = premium risk/reward for patient, disciplined traders. 🏥💪
🚀 ENGAGEMENT BOOST
✨ If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community!
🎯 Drop your entries and targets in the comments — let's build this Thief OG community together! Long 
Short 
Johnson & Johnson. Clean. Soft. Gentle. Growth.Johnson & Johnson (JNJ) stands out as a bellwether in the global healthcare sector, and its nearly 18% stock performance in 2025 reflects both robust fundamentals and compelling technical trends.
Fundamental Perspective
JNJ maintains a solid financial foundation, underpinned by consistently strong profitability, a diversified business model, and effective capital allocation. As of August 2025, JNJ reported trailing twelve-month (TTM) revenue of $90.6 billion and earnings of $22.7 billion, resulting in a net profit margin of 25% and a gross margin close to 68%. Key profitability metrics such as a Return on Assets (ROA) of 11.7%, Return on Equity (ROE) of 28.9%, and Return on Invested Capital (ROIC) of 13.6% underscore the company's operational efficiency relative to peers in the pharmaceutical industry.
From a financial health perspective, JNJ maintains moderate leverage, with a debt/equity ratio of 0.61 and an Altman-Z score of 4.17, signifying financial stability and a low risk of distress. The forward price/earnings (P/E) ratio is 14.9, suggesting that the stock is not particularly expensive for its sector, while the dividend yield remains attractive at 3.16%, appealing to income-oriented investors. The company’s free cash flow yield and high profit quality further enhance its fundamental appeal.
JNJ's growth narrative is fueled primarily by its Innovative Medicine and MedTech segments. Drugs like Darzalex and Tremfya continue to deliver high single- to double-digit year-over-year growth, and the MedTech segment is experiencing margin expansion due to scale and product mix improvements. Strategic acquisitions (notably Intra-Cellular Therapies), new regulatory approvals, and a deep late-stage pipeline (over 40 programs) provide resilience and new growth avenues, offsetting pressures from biosimilar competition, patent expirations, and legal settlements.
Technical Perspective
On the technical side, JNJ’s stock has demonstrated significant momentum. The price reached an all-time 52-week high above $170 per share in early August 2025, following Q2 earnings that exceeded expectations and prompted a nearly 6% surge in share price. Technical indicators are largely positive, with the stock trading above its 50-day and 200-day simple moving averages ($157.43 and $155.56, respectively), reflecting a prevailing bullish trend. The 14-day Relative Strength Index (RSI) stands at 55.85—neither overbought nor oversold—implying stable investor sentiment. Analyst price targets average $173, reflecting modest but continued upside.
A key technical resistance zone had developed around $167, which NYSE:JNJ has recently breached. The consensus among technical analysts is the potential for a substantial upward move towards $194 if the breakout holds, while support remains strong at around $140—historically a level where dip buyers emerge. Market sentiment remains bullish, with the Fear & Greed Index indicating broader market caution, while JNJ’s own technical indicators show "Strong Buy".
In long-term, JNJ has been supported earlier in 2025 by 10-year SMA, above which stocks are moving since 1980s, i.e. for the past 45 years (on end of year basis). In mid-term, the main technical graph indicates on major 5-year old bearish trend reversal.
Reasons for Recent Growth
JNJ’s recent growth is attributed to several convergent factors:
Strong Q2 2025 earnings performance, leading management to raise full-year revenue and EPS guidance above analysts’ expectations.
Continued strength in key growth drivers: new drug launches in oncology and immunology, robust MedTech expansion, and improved operating margins.
Favorable foreign exchange and a reduction in tariff costs, redirecting capital to R&D.
Positive pipeline developments and strategic acquisitions.
Successful navigation of legal risks and clarity regarding settlements (including talc litigation), which have reduced major uncertainties.
Broad overall market resilience and a rotation toward defensive healthcare shares.
In summary, Johnson & Johnson’s combination of strong and diversified fundamentals, attractive income profile, and bullish technical signals—amplified by improved guidance and innovation momentum—help explain the stock’s recent appreciation and continued investor confidence.
--
Best wishes,
@PandorraResearch Team
Long 
Johnson & Johnson | JNJ | Long at $146.00Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight...
While the historical simple moving average I've selected suggests the stock is entering a downtrend on the daily chart, I'm going to go against this given the current price/position it is in. If the price can hold in $140's and then move up, there could be an early cup formation here. However, if the price drops below $140, that idea is out, and the near-term downtrend may be on. But the company, overall, is a personal buy-and-hold for the long-term ups and downs (unless new news points the company in a different direction). Thus, at $146.00, NYSE:JNJ is in a personal buy-zone.
Target #1 = $157.00
Target #2 = $165.00
Target #3 = $170.00+ Long 
JOHNSON & JOHNSON Sell opportunity on a Double Resistance.It's been 9 months (October 11 2024, see chart below) since our last Johnson & Johnson (JNJ) analysis, where we gave a very timely sell signal that surgically hit our $141.00 Target:
The Channel Down has since broke to the upside and a new Higher Lows structure has emerged but with a clear Resistance Zone for the time being. At the same time, the price is also just below the Higher Highs trend-line that started on the September 04 2024 High.
With the 1D RSI overbought (same as on February 25 2025), we don't give the upside much room to go, so we turn bearish here, targeting the 0.382 Fibonacci extension and Higher Lows trend-line at $160.00.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇 Short 
US stocks hold near record highs on strong 2Q earnings
Despite elevated valuation pressures, US equities remain near all-time highs. While tariff concerns persist, resilient US economic data continues to support the market's upward momentum.
United Airlines reported a 1.7% YoY increase in 2Q revenue, citing easing geopolitical and macroeconomic uncertainties and a double-digit rebound in corporate demand. Meanwhile, earnings and share performance among mega-cap stocks have also been strong.
Netflix (NFLX) beat market expectations with 2Q revenue of $11.08 billion and EPS of $7.19. At the same time, Nvidia (NVDA) reached a fresh all-time high on renewed optimism over a potential resumption of exports to China.
After testing the support at 6285, US500 rebounded and approached its previous high again. The index holds above EMA21, suggesting the continuation of bullish momentum. If US500 remains above both EMA21 and the support at 6285, the index could breach the 6320 high. Conversely, if the US500 breaks below the support at 6285, the index could retreat further toward 6200.
Long 
Johnson & Johnson Beats Q1 Estimates, Premarket Not Doing WellJohnson & Johnson (NYSE: NYSE:JNJ ) on Tuesday reported better-than-expected Q1 results and lifted its sales forecast for the full year.
Johnson & Johnson (NYSE: NYSE:JNJ ), together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide, operating in two segments, Innovative Medicine and MedTech. Posted adjusted earnings per share (EPS) of $2.77 on revenue of $21.89 billion.
However, analysts had expected $2.56 and $21.56 billion, respectively, according to estimates compiled by Visible Alpha.
Price Action
Shares of Johnson & Johnson (NYSE: NYSE:JNJ ) were up about 1% immediately following the report, but the uptick was shortlived as the stock is down -0.54% in premarket trading. They entered the day up about 7% since the start of the year.
The company lifted its projected sales range to $91.0 billion to $91.8 billion, up from $89.2 billion to $90.0 billion previously. It also held its adjusted EPS forecast steady at $10.50 to $10.70, "including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange."
Since reporting a disappointing 2025 sales outlook in January, the company closed its nearly $15 billion acquisition of Intra-Cellular Therapies and announced plans to lift its U.S. investment to more than $55 billion over the next four years.23
Technical Outlook
Shares of NYSE:JNJ closed Monday's session up 1.73% and despite the Q1 Earnings beat, the premarket session tells a different story as the asset is down 0.54% in Tuesday's session.
The asset is trading within an enclosed rectangular formation with a perfectly formed support and resistant zones as indicated in the chart. A break above the the key moving averages could cement a bullish breakout that may resort to a break above the $169 resistant point.
With the RSI at 45.35, NYSE:JNJ is well positioned for a bullish campaign once traders digest the earnings news.
Long 
Johnson & Johnson (JNJ) Shares Drop Over 7%Johnson & Johnson (JNJ) Shares Drop Over 7%
As the chart shows, Johnson & Johnson (JNJ) shares declined by approximately 7.6%, reaching their lowest level since late February. This marked one of the worst performances in the stock market yesterday.
Why Did JNJ Shares Fall?
Two major bearish factors contributed to the decline:
A Texas judge rejected Johnson & Johnson's third attempt to settle lawsuits related to allegations that its baby powder and other talc-based products harmed consumers.
On Tuesday, Johnson & Johnson announced that its upcoming acquisition of Intra-Cellular Therapies is expected to dilute adjusted earnings per share by approximately $0.25 for the full year 2025. Investors appear to have reacted negatively to this outlook, despite the company’s expectation that the deal will generate around $700 million in additional sales.
Technical Analysis of JNJ Stock Chart
Price movements in 2025 have formed an ascending channel (marked in blue), with indicators highlighting how:
→ The channel’s boundaries have acted as support and resistance levels.
→ The channel’s median line has served as a “magnet” for price action, reflecting the balance between supply and demand.
As JNJ's share price approaches the lower boundary (circled), just above the psychological support level at $150—previously a key level in February—traders have reasons to anticipate that the decline may slow down or even lead to a significant rebound from this support area.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice. Cracks Appearing in J&J's Armor?Johnson & Johnson, a long-established leader in the global healthcare sector, confronts substantial challenges that raise significant questions about its future trajectory and stock valuation. Foremost among these is the persistent and massive litigation surrounding its talc-based baby powder. With tens of thousands of lawsuits alleging links to cancer, the company's strategy to manage this liability via bankruptcy has been repeatedly struck down by courts, most recently rejecting a $10 billion settlement proposal. This forces J&J to potentially face over 60,000 individual claims in court, introducing immense financial uncertainty and the prospect of staggering legal costs and damages.
Compounding these concerns is mounting scrutiny over the company's historical and recent marketing practices. A federal judge recently imposed a $1.64 billion penalty against J&J's pharmaceutical arm for misleading marketing of HIV medications, citing a "deliberate and calculated scheme." This follows earlier multi-million dollar settlements related to alleged improper financial inducements paid to surgeons for orthopaedic implants by its DePuy subsidiary, and tax disputes in India over questionable "professional sponsorship" expenses tied to similar activities. These incidents depict recurring legal and ethical entanglements with significant financial penalties and reputational harm.
Taken together, the unresolved talc litigation, substantial financial penalties from marketing violations, and persistent questions regarding ethical conduct create considerable headwinds for Johnson & Johnson. The cumulative impact of ongoing legal battles, potential future liabilities, and damage to its corporate image threatens to drain resources, divert management focus from core operations, and erode investor confidence. These converging factors present tangible risks that could exert significant downward pressure on the company's stock price moving forward. Short 
The Next Big Healthcare Stock?The chart for VERV shows a prolonged downtrend since mid-2021, with multiple resistance trendlines capping price action. However, the stock is now testing a potential breakout above these trendlines and the 50-week EMA (green line), which has acted as dynamic resistance. The RSI is rising above 60, signaling increasing bullish momentum, and the latest weekly candle, up 11.28%, suggests growing buying interest. If VERV successfully holds above this breakout zone, it could push toward the $10-$15 resistance range, confirming a trend shift. However, failure to sustain above the 50EMA could result in another rejection, reinforcing the downtrend. Volume is picking up, adding weight to the bullish case, but confirmation above key levels remains crucial for a sustained move higher.
Disclaimer:
This analysis is for educational purposes only and should not be considered financial advice. Trading and investing involve risk, and independent research or consultation with a professional is recommended before making any financial decisions.
